NMN, a dietary supplement derived from vitamin B3, is taken to restore an energy and repair molecule that declines with age. It consistently raises that molecule in the blood. Small, short, often company-funded trials show a small drop in the lower blood-pressure number and moderate gains in endurance and self-rated health. Short-term safety looks good; long-term use remains an open question, and slower aging in people is untested. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Whole-blood NAD+ | No established target; track change from own baseline | Confirms uptake |
| Fasting glucose | 70–99 mg/dL | Safety check (additive glucose lowering with diabetes drugs) |
| Blood pressure | Below 120/80 mmHg | Expected to change (diastolic) |
| ALT and AST | ALT 7–56 U/L; AST 10–40 U/L | Safety check (liver) |
| eGFR and creatinine | eGFR 60 mL/min/1.73 m² or higher | Safety check (kidney clearance of metabolites) |
| Homocysteine | 5–15 µmol/L | Safety check (methyl-group drain) |
Cadence: Baseline before starting; NAD+, glucose and blood pressure at 8–12 weeks, then every 6–12 months; liver, kidney and homocysteine checks every 6 months at doses above 600 mg/day.